Suppr超能文献

治疗性酶人胸苷磷酸化酶的重组表达及聚乙二醇化效率工程

Engineering of the Recombinant Expression and PEGylation Efficiency of the Therapeutic Enzyme Human Thymidine Phosphorylase.

作者信息

Karamitros Christos S, Somody Catrina M, Agnello Giulia, Rowlinson Scott

机构信息

Aeglea Biotherapeutics, Austin, TX, United States.

出版信息

Front Bioeng Biotechnol. 2021 Dec 17;9:793985. doi: 10.3389/fbioe.2021.793985. eCollection 2021.

Abstract

Human thymidine phosphorylase (HsTP) is an enzyme with important implications in the field of rare metabolic diseases. Defective mutations of HsTP lead to mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a disease with a high unmet medical need that is associated with severe neurological and gastrointestinal complications. Current efforts focus on the development of an enzyme replacement therapy (ERT) using the ortholog (EcTP). However, bacterial enzymes are counter-indicated for human therapeutic applications because they are recognized as foreign by the human immune system, thereby eliciting adverse immune responses and raising significant safety and efficacy risks. Thus, it is critical to utilize the HsTP enzyme as starting scaffold for pre-clinical drug development, thus de-risking the safety concerns associated with the use of bacterial enzymes. However, HsTP expresses very poorly in , whereas its PEGylation, a crucial chemical modification for achieving long serum persistence of therapeutic enzymes, is highly inefficient and negatively affects its catalytic activity. Here we focused on the engineering of the recombinant expression profile of HsTP in cells, as well as on the optimization of its PEGylation efficiency aiming at the development of an alternative therapeutic approach for MNGIE. We show that phylogenetic and structural analysis of proteins can provide important insights for the rational design of N'-terminus-truncation constructs which exhibit significantly improved recombinant expression levels. In addition, we developed and implemented a criteria-driven rational surface engineering strategy for the substitution of arginine-to-lysine and lysine-to-arginine residues to achieve more efficient, homogeneous and reproducible PEGylation without negatively affecting the enzymatic catalytic activity upon PEGylation. Collectively, our proposed strategies provide an effective way to optimize enzyme PEGylation and recombinant expression and are likely applicable for other proteins and enzymes.

摘要

人胸苷磷酸化酶(HsTP)是一种在罕见代谢疾病领域具有重要意义的酶。HsTP的缺陷突变会导致线粒体神经胃肠性脑肌病(MNGIE),这是一种存在大量未满足医疗需求的疾病,与严重的神经和胃肠道并发症相关。目前的努力集中在开发使用直系同源物(EcTP)的酶替代疗法(ERT)。然而,细菌酶不适合用于人类治疗应用,因为它们会被人体免疫系统识别为外来物质,从而引发不良免疫反应,并带来重大的安全和疗效风险。因此,利用HsTP酶作为临床前药物开发的起始支架至关重要,从而降低与使用细菌酶相关的安全问题风险。然而,HsTP在[具体细胞类型未提及]中表达非常低,而其聚乙二醇化(PEGylation),这是实现治疗性酶在血清中长效存在的关键化学修饰,效率极低且会对其催化活性产生负面影响。在这里,我们专注于优化HsTP在[具体细胞类型未提及]细胞中的重组表达谱,以及优化其聚乙二醇化效率,旨在开发一种针对MNGIE的替代治疗方法。我们表明,蛋白质的系统发育和结构分析可为合理设计N端截短构建体提供重要见解,这些构建体的重组表达水平显著提高。此外,我们开发并实施了一种基于标准的合理表面工程策略,用于精氨酸到赖氨酸和赖氨酸到精氨酸残基的替换,以实现更高效、均匀且可重复的聚乙二醇化,同时在聚乙二醇化后不会对酶的催化活性产生负面影响。总体而言,我们提出的策略为优化酶的聚乙二醇化和重组表达提供了一种有效方法,并且可能适用于其他蛋白质和酶。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/780a/8718881/70e3796e47d9/fbioe-09-793985-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验